Qiagen (NYSE:QGEN) Updates FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.280- for the period, compared to the consensus estimate of 2.350. The company issued revenue guidance of $2.1 billion-, compared to the consensus revenue estimate of $2.1 billion. Qiagen also updated its Q1 2025 guidance to 0.500- EPS.

Qiagen Stock Down 2.6 %

QGEN stock traded down $1.11 during midday trading on Friday, hitting $41.34. The company's stock had a trading volume of 1,306,855 shares, compared to its average volume of 1,330,707. The firm's 50-day moving average is $43.78 and its 200-day moving average is $43.25. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 12 month low of $40.15 and a 12 month high of $49.30. The company has a market cap of $9.17 billion, a PE ratio of 115.09, a P/E/G ratio of 3.29 and a beta of 0.36.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.97% and a net margin of 4.23%. On average, equities research analysts forecast that Qiagen will post 2.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on QGEN shares. HSBC lowered shares of Qiagen from a "buy" rating to a "hold" rating and set a $47.64 price target for the company. in a research note on Thursday, October 17th. Jefferies Financial Group reissued a "buy" rating and set a $52.50 price target (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. UBS Group dropped their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday. Hsbc Global Res upgraded Qiagen to a "hold" rating in a research report on Thursday, October 17th. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $46.67 target price (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $48.78.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.